A Phase 3 interventional study of Bortezomib + Rituximab and Rituximab in Non-Hodgkin's Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 206 sites in 32 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-25.
Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies testing bortezomib in Lymphoma, Non-Hodgkin — none open to participants now, none under way, none of them phase 3. Bortezomib · Lymphoma, Non-Hodgkin.
Among the 35 studies testing bortezomib in Lymphoma, Non-Hodgkin, this one has the largest enrollment of the 32 interventional ones that give a count, is one of 8 that started in 2006, is the only one in phase 3, and was the 13th registered.
2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.
Browse Lymphoma, Non-Hodgkin studies →None of the 35 studies testing bortezomib in Lymphoma, Non-Hodgkin is open now. The open studies under Lymphoma, Non-Hodgkin, anywhere →
Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 22 · Phase 3 1
First in 1999; this study’s year is marked. 8 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 676 is above the median of 40 across 1,883 interventional studies indexed under Lymphoma, Non-Hodgkin.
Median enrollment 33 across the 32 interventional studies. Of the 34 that completed or were terminated, 19 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 35 have an industry lead sponsor. The 10 most frequent:
This study is registered under Millennium Pharmaceuticals, Inc., one of the names counted as Takeda. Under that name alone:
Millennium Pharmaceuticals, Inc. is the lead sponsor of 178 studies on the registry; none are open to participants now.
Of its 74 completed or terminated interventional studies of FDA-regulated products, 73 (99%) have results posted.
Takeda has 8 studies filed under Lymphoma, Non-Hodgkin — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 35 studies testing bortezomib in Lymphoma, Non-Hodgkin, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if the combination of VELCADE and rituximab improves progression free survival relative to rituximab alone in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma (B-NHL) who never received rituximab or who have previously responded to rituximab. This is an international study being conducted in the United States and in many countries around the world. A complete list of study locations is listed below.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Subjects must satisfy the following criteria to be enrolled in the study:
If any prior regimen included rituximab, the subject must have responded (complete response [CR], unconfirmed complete response [CRu], partial response [PR]), and the time to progression (TTP) from the first dose of rituximab must have been 6 months or more.
Exclusion Criteria:
Potential subjects who meet any of the following criteria will be excluded from participating in the study:
History of disallowed therapies:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Bortezomib + Rituximab
Drug: Rituximab
Drug pages: Bortezomib · Rituximab
VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.
rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).
Progression Free Survival
Progression free survival is defined as time from randomization to progressive disease or death due to any cause, whichever occurs first.
Time frame: Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months.
Overall Response Rate
Overall response rate is defined as Complete Response (CR) + Complete Response Unconfirmed (CRu) + Partial Response (PR) using International Working Group Criteria (IWGC) and Independent Radiographic Review results and clinical results. The IWGC CR requires complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms, and normalization of lactic dehydrogenase and bone marrow involvement. CRu requires more than 75% reduction in sum of product of nodes (SPD). PR requires moer than 50% reduction in SPD.
Time frame: Subjects are followed until progressive disease/death or the end of the study. The median follow up time is 33.9 months.
| Milestone | Bortezomib + Rituximab | Rituximab |
|---|---|---|
| Started | 336 | 340 |
| Completed | 237 | 245 |
| Not completed | 99 | 95 |
| Withdrew: Adverse event | 19 | 5 |
| Withdrew: Death | 2 | 2 |
| Withdrew: Withdrawal by subject | 14 | 6 |
| Withdrew: Disease progression | 56 | 77 |
| Withdrew: Lost to follow-up | 2 | 0 |
| Withdrew: Other | 6 | 5 |
Progression free survival is defined as time from randomization to progressive disease or death due to any cause, whichever occurs first.
| days | Bortezomib + Rituximab | Rituximab |
|---|---|---|
| Progression Free Survival | 389 (351 to 456) | 334 (278 to 365) |
Overall response rate is defined as Complete Response (CR) + Complete Response Unconfirmed (CRu) + Partial Response (PR) using International Working Group Criteria (IWGC) and Independent Radiographic Review results and clinical results. The IWGC CR requires complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms, and normalization of lactic dehydrogenase and bone marrow involvement. CRu requires more than 75% reduction in sum of product of nodes (SPD). PR requires moer than 50% reduction in SPD.
| participants | Bortezomib + Rituximab | Rituximab |
|---|---|---|
| Overall Response Rate | 199 | 160 |
Collected over the end of study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bortezomib + Rituximab | — | 59/334 (17.7%) | 288/334 (86.2%) |
| Rituximab | — | 37/339 (10.9%) | 232/339 (68.4%) |
| Event | Bortezomib + Rituximab | Rituximab |
|---|---|---|
| PneumoniaInfections and infestations | 7/334 | 3/339 |
| PyrexiaGeneral disorders | 6/334 | 2/339 |
| DiarrhoeaGastrointestinal disorders | 5/334 | 2/339 |
| Febrile neutropeniaBlood and lymphatic system disorders | 5/334 | 3/339 |
| Herpes zosterInfections and infestations | 4/334 | 0/339 |
| VomitingGastrointestinal disorders | 4/334 | 1/339 |
| HypersensitivityImmune system disorders | 4/334 | 1/339 |
| HypotensionVascular disorders | 4/334 | 0/339 |
| SepsisInfections and infestations | 3/334 | 0/339 |
| Abdominal painGastrointestinal disorders | 2/334 | 2/339 |
| Event | Bortezomib + Rituximab | Rituximab |
|---|---|---|
| FatigueGeneral disorders | 75/334 | 27/339 |
| CoughRespiratory, thoracic and mediastinal disorders | 51/334 | 31/339 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 46/334 | 15/339 |
| HeadacheNervous system disorders | 42/334 | 24/339 |
| ParaesthesiaNervous system disorders | 39/334 | 10/339 |
| Back painMusculoskeletal and connective tissue disorders | 37/334 | 25/339 |
| ThrombocytopeniaBlood and lymphatic system disorders | 32/334 | 13/339 |
| InsomniaPsychiatric disorders | 30/334 | 18/339 |
| ChillsGeneral disorders | 28/334 | 17/339 |
| PruritusSkin and subcutaneous tissue disorders | 25/334 | 15/339 |
| Age, Categorical(Participants) | Bortezomib + Rituximab | Rituximab | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 243 | 242 | 485 |
| >=65 years | 93 | 98 | 191 |
| Age Continuous(years) | Bortezomib + Rituximab | Rituximab | Total |
|---|---|---|---|
| Mean | 56.8 ± 11.12 | 57.3 ± 12 | 57 ± 11.56 |
| Sex: Female, Male(Participants) | Bortezomib + Rituximab | Rituximab | Total |
|---|---|---|---|
| Female | 164 | 203 | 367 |
| Male | 172 | 137 | 309 |
| Region of Enrollment(participants) | Bortezomib + Rituximab | Rituximab | Total |
|---|---|---|---|
| United States | 14 | 16 | 30 |
| Portugal | 11 | 12 | 23 |
| Slovakia | 7 | 8 | 15 |
| Greece | 1 | 1 | 2 |
| Thailand | 2 | 1 | 3 |
| Spain | 9 | 5 | 14 |
| Ukraine | 13 | 11 | 24 |
| Israel | 7 | 7 | 14 |
| Russian Federation | 52 | 55 | 107 |
| Italy | 14 | 15 | 29 |
| India | 17 | 24 | 41 |
| France | 13 | 10 | 23 |
| Australia | 5 | 3 | 8 |
| South Africa | 2 | 2 | 4 |
| China | 46 | 40 | 86 |
| Korea, Republic of | 4 | 3 | 7 |
| Finland | 1 | 2 | 3 |
| United Kingdom | 9 | 10 | 19 |
| Hungary | 3 | 6 | 9 |
| Czech Republic | 18 | 17 | 35 |
| Mexico | 9 | 8 | 17 |
| Canada | 9 | 10 | 19 |
| Argentina | 2 | 5 | 7 |
| Brazil | 18 | 21 | 39 |
| Belgium | 18 | 19 | 37 |
| Poland | 24 | 21 | 45 |
| Romania | 6 | 2 | 8 |
| Germany | 0 | 3 | 3 |
| Sweden | 2 | 3 | 5 |
Showing the first 100 of 206 sites across 32 countries. Choose a country and city above to see the rest.
The record gives a start of Mar 2006, a primary completion of Jun 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bortezomib · Rituximab
Millennium Pharmaceuticals, Inc. →